Sun Pharma to acquire Innovcare Lifesciences for ₹271.2 crore

1 min read Updated on 21 Jun 2026, 12:52 AM

Reviewed by

Naman SScanX News Team

AI Summary

Sun Pharmaceutical Industries Limited has agreed to acquire 100% of Innovcare Lifesciences Private Limited for ₹271.2 crore. The strategic investment aims to strengthen Sun Pharma's product portfolio and is expected to close by 31 July 2026 without requiring regulatory approvals.

*this image is generated using AI for illustrative purposes only.

Sun Pharmaceutical Industries Limited has agreed to acquire 100% of the outstanding shares of Innovcare Lifesciences Private Limited for a cash consideration of approximately ₹271.2 crore. The acquisition is a strategic investment intended to strengthen the product portfolio of Sun Pharmaceutical Industries Limited . The transaction is expected to be completed on or before 31 July 2026.

Innovcare Lifesciences, a Mumbai-based company incorporated on 21 July 2014, is engaged in the marketing, distribution, and sale of pharmaceutical drugs, nutraceutical, and cosmeceutical products. The company operates solely within India and reported revenue from operations of ₹94.06 crore for FY 2025-26.

The acquisition is not a related party transaction, and the promoter or promoter group of Sun Pharma does not hold any interest in Innovcare Lifesciences. No governmental or regulatory approvals are required for the completion of this transaction, and the consideration will be paid entirely in cash.

Financial Performance of Innovcare Lifesciences

Innovcare Lifesciences has demonstrated consistent revenue growth over the past three financial years, as detailed below:

Financial Year:	Revenue from Operations (₹ Crore)
FY 2025-26	94.06
FY 2024-25	86.09
FY 2023-24	80.93

This acquisition aligns with Sun Pharma's strategy to expand its presence in the pharmaceutical and healthcare sectors.

Historical Stock Returns for Sun Pharmaceutical

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.16%	+1.86%	-2.18%	+5.52%	+11.76%	+174.27%

How will this acquisition impact Sun Pharma's market share in the domestic Indian pharmaceutical sector?

What specific product categories within Innovcare's portfolio are expected to drive the most value for Sun Pharma?

Does Sun Pharma plan to pursue further acquisitions to complement this deal and expand its healthcare offerings?

Read Next Article

Sun Pharma intimation of arrest of Independent Director Gautam Doshi

0 min read Updated on 15 Jun 2026, 04:37 PM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

AI Summary

Sun Pharmaceutical Industries Ltd disclosed the arrest of Independent Director Gautam Doshi, stating the matter is unrelated to operations and will not impact the company or its Board processes. The intimation was filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with exchanges on June 14, 2026. The company will monitor the situation and take appropriate steps based on further developments.

*this image is generated using AI for illustrative purposes only.

Sun Pharmaceutical Industries Ltd disclosed the arrest of its Independent Director, Mr. Gautam Doshi. The company clarified that the matter is not connected with its operations and no impact is envisaged on the company or its Board processes. The information was submitted to the National Stock Exchange of India Limited and BSE Limited on June 14, 2026.

The intimation was filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sun Pharmaceutical Industries Limited stated that it will continue to monitor the situation. Appropriate steps will be taken by the company based on further developments regarding the arrest.

The filing was signed by Anoop Anjanikumar Deshpande, Company Secretary and Compliance Officer, on behalf of Sun Pharmaceutical Industries Limited.

Historical Stock Returns for Sun Pharmaceutical